Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VSA006 · 1 trial · 1 indication
No Worsening of NASH is defined as no increase in inflammation, ballooning, or steatosis scores in the NAS score.
NASH Improvement indicates a reduction by at least 2 points in the NAS score, with at least one-point reduction in ballooning without increase in steatosis score.
| Arm | Type | Description |
|---|---|---|
| VSA006 low dose | EXPERIMENTAL | - |
| VSA006 low dose comparator | PLACEBO_COMPARATOR | - |
| VSA006 high dose | EXPERIMENTAL | - |
| VSA006 high dose comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VSA006 | DRUG | every 12 weeks, subcutaneous injections |
| Placebo | DRUG | every 12 weeks, subcutaneous injections |
Inclusion Criteria: * body mass index (BMI) of 24-35 kg/m2 ; * NASH patients confirmed by liver histopathology: NAS score is ≥ 4 and CRN fibrosis is F2 or F3 ; * At screening, ALT is \> ULN; * At screening, the liver fat content measured by MRI-PDFF is ≥ 8%; * Weight change \< 5% at least 3 months ...
VSA006 is an investigational small molecule being developed for the treatment of non-alcoholic steatohepatitis (NASH), a metabolic liver condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
VSA006 is being developed by Arrowhead Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ARWR. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with NASH.
VSA006 is in Phase 2 clinical development. It is currently being evaluated in an active, placebo-controlled, double-blind, randomized trial in China, with a planned enrollment of 48 participants. The drug is investigational and not yet approved.
VSA006 is being studied in a Phase 2 clinical trial registered as NCT06322628, titled 'A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients.' The trial is active but not recruiting, with 48 participants enrolled in China.
No alternative names for VSA006 have been disclosed. The drug is identified solely by its code name VSA006 in clinical trial registrations and is being developed by Arrowhead Pharmaceuticals.